AU706594B2 - Treatment of traumatic brain injury - Google Patents

Treatment of traumatic brain injury Download PDF

Info

Publication number: AU706594B2
Authority: AU; Australia
Prior art keywords: treatment; tetrahydro; tetrazol; ethyl; methylpyridine
Prior art date: 1995-11-06
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Ceased

Application number

AU74900/96A

Other languages

English (en)

Other versions

AU7490096A (en

Inventor

Brian R. Pike

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

H Lundbeck AS

Original Assignee

H Lundbeck AS

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-11-06

Filing date

1996-11-05

Publication date

1999-06-17

1996-11-05 Application filed by H Lundbeck AS filed Critical H Lundbeck AS

1997-05-29 Publication of AU7490096A publication Critical patent/AU7490096A/en

1999-06-17 Application granted granted Critical

1999-06-17 Publication of AU706594B2 publication Critical patent/AU706594B2/en

2016-11-05 Anticipated expiration legal-status Critical

Status Ceased legal-status Critical Current

Links

208000030886 Traumatic Brain injury Diseases 0.000 title claims description 25
230000009529 traumatic brain injury Effects 0.000 title claims description 25
RNMOMKCRCIRYCZ-UHFFFAOYSA-N Alvameline Chemical compound CCN1N=NC(C=2CN(C)CCC=2)=N1 RNMOMKCRCIRYCZ-UHFFFAOYSA-N 0.000 claims description 12
150000003839 salts Chemical class 0.000 claims description 12
239000002253 acid Substances 0.000 claims description 8
239000000825 pharmaceutical preparation Substances 0.000 claims description 6
238000004519 manufacturing process Methods 0.000 claims description 3
230000000926 neurological effect Effects 0.000 claims description 3
208000030507 AIDS Diseases 0.000 claims description 2
206010008088 Cerebral artery embolism Diseases 0.000 claims description 2
206010008111 Cerebral haemorrhage Diseases 0.000 claims description 2
206010008132 Cerebral thrombosis Diseases 0.000 claims description 2
206010010254 Concussion Diseases 0.000 claims description 2
208000010496 Heart Arrest Diseases 0.000 claims description 2
201000001429 Intracranial Thrombosis Diseases 0.000 claims description 2
230000002490 cerebral effect Effects 0.000 claims description 2
230000009514 concussion Effects 0.000 claims description 2
201000002491 encephalomyelitis Diseases 0.000 claims description 2
208000003906 hydrocephalus Diseases 0.000 claims description 2
208000015181 infectious disease Diseases 0.000 claims description 2
201000010849 intracranial embolism Diseases 0.000 claims description 2
201000009941 intracranial hypertension Diseases 0.000 claims description 2
208000028867 ischemia Diseases 0.000 claims description 2
230000002980 postoperative effect Effects 0.000 claims description 2
230000029058 respiratory gaseous exchange Effects 0.000 claims description 2
210000003625 skull Anatomy 0.000 claims 1
150000001875 compounds Chemical group 0.000 description 16
208000014674 injury Diseases 0.000 description 14
208000027418 Wounds and injury Diseases 0.000 description 13
241001465754 Metazoa Species 0.000 description 12
230000006378 damage Effects 0.000 description 12
238000012360 testing method Methods 0.000 description 8
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
238000000034 method Methods 0.000 description 7
210000002569 neuron Anatomy 0.000 description 7
210000004129 prosencephalon Anatomy 0.000 description 7
239000000243 solution Substances 0.000 description 7
230000037396 body weight Effects 0.000 description 6
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
210000002813 septal nuclei Anatomy 0.000 description 6
239000011780 sodium chloride Substances 0.000 description 6
241000700159 Rattus Species 0.000 description 5
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
239000002953 phosphate buffered saline Substances 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
ZHAFUINZIZIXFC-UHFFFAOYSA-N [9-(dimethylamino)-10-methylbenzo[a]phenoxazin-5-ylidene]azanium;chloride Chemical compound [Cl-].O1C2=CC(=[NH2+])C3=CC=CC=C3C2=NC2=C1C=C(N(C)C)C(C)=C2 ZHAFUINZIZIXFC-UHFFFAOYSA-N 0.000 description 4
239000004480 active ingredient Substances 0.000 description 4
210000004027 cell Anatomy 0.000 description 4
230000000694 effects Effects 0.000 description 4
239000008101 lactose Substances 0.000 description 4
230000009467 reduction Effects 0.000 description 4
238000010825 rotarod performance test Methods 0.000 description 4
230000001629 suppression Effects 0.000 description 4
239000003826 tablet Substances 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
229920002261 Corn starch Polymers 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
239000000654 additive Substances 0.000 description 3
239000002671 adjuvant Substances 0.000 description 3
210000002932 cholinergic neuron Anatomy 0.000 description 3
239000012530 fluid Substances 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
235000019359 magnesium stearate Nutrition 0.000 description 3
239000000203 mixture Substances 0.000 description 3
102000005962 receptors Human genes 0.000 description 3
108020003175 receptors Proteins 0.000 description 3
230000028527 righting reflex Effects 0.000 description 3
239000003656 tris buffered saline Substances 0.000 description 3
GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 2
208000024827 Alzheimer disease Diseases 0.000 description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
235000019759 Maize starch Nutrition 0.000 description 2
229920000168 Microcrystalline cellulose Polymers 0.000 description 2
238000012347 Morris Water Maze Methods 0.000 description 2
102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 2
108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 2
235000011054 acetic acid Nutrition 0.000 description 2
230000000996 additive effect Effects 0.000 description 2
238000000540 analysis of variance Methods 0.000 description 2
210000004556 brain Anatomy 0.000 description 2
230000001713 cholinergic effect Effects 0.000 description 2
229940125758 compound 15 Drugs 0.000 description 2
229960003368 croscarmellose sodium type a Drugs 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
239000003814 drug Substances 0.000 description 2
229940079593 drug Drugs 0.000 description 2
238000009472 formulation Methods 0.000 description 2
239000001863 hydroxypropyl cellulose Substances 0.000 description 2
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
238000003384 imaging method Methods 0.000 description 2
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
235000019813 microcrystalline cellulose Nutrition 0.000 description 2
239000008108 microcrystalline cellulose Substances 0.000 description 2
229940016286 microcrystalline cellulose Drugs 0.000 description 2
230000002536 noncholinergic effect Effects 0.000 description 2
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
238000009527 percussion Methods 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
AUFIRGPROMANKW-UHFFFAOYSA-N 1-methyl-3,6-dihydro-2h-pyridine Chemical compound CN1CCC=CC1 AUFIRGPROMANKW-UHFFFAOYSA-N 0.000 description 1
VZPDPKFEKOJCSQ-UHFFFAOYSA-N 5-(2h-tetrazol-5-yl)-1,2,3,6-tetrahydropyridine Chemical class C1NCCC=C1C1=NN=NN1 VZPDPKFEKOJCSQ-UHFFFAOYSA-N 0.000 description 1
SKTFQHRVFFOHTQ-UHFFFAOYSA-N 8-bromo-1,3-dimethyl-7h-purine-2,6-dione Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC(Br)=N2 SKTFQHRVFFOHTQ-UHFFFAOYSA-N 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
108010009685 Cholinergic Receptors Proteins 0.000 description 1
239000001828 Gelatine Substances 0.000 description 1
102000007207 Muscarinic M1 Receptor Human genes 0.000 description 1
108010008406 Muscarinic M1 Receptor Proteins 0.000 description 1
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical class O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
229930040373 Paraformaldehyde Natural products 0.000 description 1
WINXNKPZLFISPD-UHFFFAOYSA-M Saccharin sodium Chemical compound [Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 WINXNKPZLFISPD-UHFFFAOYSA-M 0.000 description 1
206010039966 Senile dementia Diseases 0.000 description 1
ZFXYFBGIUFBOJW-UHFFFAOYSA-N Theophylline Natural products O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
239000013504 Triton X-100 Substances 0.000 description 1
102000034337 acetylcholine receptors Human genes 0.000 description 1
230000002411 adverse Effects 0.000 description 1
239000003708 ampul Substances 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
230000001174 ascending effect Effects 0.000 description 1
230000002238 attenuated effect Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
239000002775 capsule Substances 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
230000030833 cell death Effects 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
229960001231 choline Drugs 0.000 description 1
230000003920 cognitive function Effects 0.000 description 1
230000003931 cognitive performance Effects 0.000 description 1
238000004040 coloring Methods 0.000 description 1
238000012790 confirmation Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
239000012458 free base Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
239000011521 glass Substances 0.000 description 1
125000000623 heterocyclic group Chemical group 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
210000002425 internal capsule Anatomy 0.000 description 1
230000006386 memory function Effects 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
229960002216 methylparaben Drugs 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
238000002156 mixing Methods 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
230000004770 neurodegeneration Effects 0.000 description 1
229910052759 nickel Inorganic materials 0.000 description 1
PXHVJJICTQNCMI-UHFFFAOYSA-N nickel Substances [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
229920002866 paraformaldehyde Polymers 0.000 description 1
239000004031 partial agonist Substances 0.000 description 1
229960001412 pentobarbital Drugs 0.000 description 1
230000010412 perfusion Effects 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
150000003053 piperidines Chemical class 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229940069328 povidone Drugs 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
229960003415 propylparaben Drugs 0.000 description 1
238000011002 quantification Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
230000000392 somatic effect Effects 0.000 description 1
230000006886 spatial memory Effects 0.000 description 1
210000000278 spinal cord Anatomy 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
238000005556 structure-activity relationship Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
229960000278 theophylline Drugs 0.000 description 1
-1 theophylline acetic acids Chemical class 0.000 description 1
230000008733 trauma Effects 0.000 description 1
239000008215 water for injection Substances 0.000 description 1
239000008096 xylene Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

AU74900/96A 1995-11-06 1996-11-05 Treatment of traumatic brain injury Ceased AU706594B2 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
DK1232/95		1995-11-06
DK123295		1995-11-06
PCT/DK1996/000458 WO1997017074A1 (en)	1995-11-06	1996-11-05	Treatment of traumatic brain injury

Publications (2)

Publication Number	Publication Date
AU7490096A AU7490096A (en)	1997-05-29
AU706594B2 true AU706594B2 (en)	1999-06-17

Family

ID=8102484

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU74900/96A Ceased AU706594B2 (en)	1995-11-06	1996-11-05	Treatment of traumatic brain injury

Country Status (18)

Country	Link
EP (1)	EP0866706A1 (cs)
JP (1)	JPH11514654A (cs)
KR (1)	KR19990067353A (cs)
AU (1)	AU706594B2 (cs)
BG (1)	BG63150B1 (cs)
BR (1)	BR9611396A (cs)
CA (1)	CA2234824A1 (cs)
CZ (1)	CZ287441B6 (cs)
EA (1)	EA000531B1 (cs)
HU (1)	HUP9901051A2 (cs)
IS (1)	IS4726A (cs)
NO (1)	NO982036L (cs)
NZ (1)	NZ321546A (cs)
PL (1)	PL326490A1 (cs)
SK (1)	SK58198A3 (cs)
TR (1)	TR199800801T2 (cs)
WO (1)	WO1997017074A1 (cs)
ZA (1)	ZA969320B (cs)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR013096A1 (es) *	1997-07-01	2000-12-13	Lundbeck & Co As H	Sal de adicion de acido maleico de 5-(2-etil-2-h-tetrazol-5-il)-1-metil- 1,2,3,6-tetrahidropiridina, composicion farmaceutica que la contiene, su usoen terapia y metodo de preparacion de la misma.
RU2266737C1 (ru) *	2004-04-12	2005-12-27	Тихоокеанский Институт Биоорганической Химии Дальневосточного Отделения Россиской Академии Наук	Препарат для лечения геморрагического инсульта и способ лечения геморрагического инсульта
EP2258358A3 (en)	2005-08-26	2011-09-07	Braincells, Inc.	Neurogenesis with acetylcholinesterase inhibitor
EP2275095A3 (en)	2005-08-26	2011-08-17	Braincells, Inc.	Neurogenesis by muscarinic receptor modulation
EP1940389A2 (en)	2005-10-21	2008-07-09	Braincells, Inc.	Modulation of neurogenesis by pde inhibition
AU2006308889A1 (en)	2005-10-31	2007-05-10	Braincells, Inc.	GABA receptor mediated modulation of neurogenesis
US20100216734A1 (en)	2006-03-08	2010-08-26	Braincells, Inc.	Modulation of neurogenesis by nootropic agents
EP2382975A3 (en)	2006-05-09	2012-02-29	Braincells, Inc.	Neurogenesis by modulating angiotensin
US20100184806A1 (en)	2006-09-19	2010-07-22	Braincells, Inc.	Modulation of neurogenesis by ppar agents
WO2010099217A1 (en)	2009-02-25	2010-09-02	Braincells, Inc.	Modulation of neurogenesis using d-cycloserine combinations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8714789D0 (en) *	1987-06-24	1987-07-29	Lundbeck & Co As H	Heterocyclic compounds
US5328925A (en) *	1989-02-22	1994-07-12	Novo Nordisk A/S	Piperidine compounds and their use
IE922270A1 (en) *	1991-07-26	1993-01-27	Akzo Nv	Pyrazole derivatives
US5330994A (en) *	1992-03-24	1994-07-19	Warner-Lambert Company	Tetrahydropyridine isoxazoline derivatives

1996
- 1996-11-05 HU HU9901051A patent/HUP9901051A2/hu unknown
- 1996-11-05 JP JP9517762A patent/JPH11514654A/ja active Pending
- 1996-11-05 EP EP96937193A patent/EP0866706A1/en not_active Ceased
- 1996-11-05 BR BR9611396A patent/BR9611396A/pt not_active Application Discontinuation
- 1996-11-05 CZ CZ19981389A patent/CZ287441B6/cs not_active IP Right Cessation
- 1996-11-05 EA EA199800434A patent/EA000531B1/ru not_active IP Right Cessation
- 1996-11-05 KR KR1019980703360A patent/KR19990067353A/ko not_active Ceased
- 1996-11-05 PL PL96326490A patent/PL326490A1/xx unknown
- 1996-11-05 NZ NZ321546A patent/NZ321546A/xx unknown
- 1996-11-05 TR TR1998/00801T patent/TR199800801T2/xx unknown
- 1996-11-05 SK SK581-98A patent/SK58198A3/sk unknown
- 1996-11-05 WO PCT/DK1996/000458 patent/WO1997017074A1/en not_active Ceased
- 1996-11-05 AU AU74900/96A patent/AU706594B2/en not_active Ceased
- 1996-11-05 CA CA002234824A patent/CA2234824A1/en not_active Abandoned
- 1996-11-06 ZA ZA969320A patent/ZA969320B/xx unknown
1998
- 1998-04-27 IS IS4726A patent/IS4726A/is unknown
- 1998-05-05 NO NO982036A patent/NO982036L/no not_active Application Discontinuation
- 1998-05-22 BG BG102480A patent/BG63150B1/bg unknown

Also Published As

Publication number	Publication date
EP0866706A1 (en)	1998-09-30
NZ321546A (en)	2000-12-22
SK58198A3 (en)	1998-10-07
TR199800801T2 (xx)	1998-08-21
ZA969320B (en)	1997-05-30
CZ287441B6 (en)	2000-11-15
AU7490096A (en)	1997-05-29
NO982036L (no)	1998-06-25
EA000531B1 (ru)	1999-10-28
BR9611396A (pt)	1999-07-13
MX9803432A (es)	1998-09-30
KR19990067353A (ko)	1999-08-16
WO1997017074A1 (en)	1997-05-15
CA2234824A1 (en)	1997-05-15
BG102480A (en)	1999-01-29
IS4726A (is)	1998-04-27
HUP9901051A2 (hu)	2000-03-28
JPH11514654A (ja)	1999-12-14
EA199800434A1 (ru)	1998-10-29
NO982036D0 (no)	1998-05-05
CZ138998A3 (cs)	1998-10-14
BG63150B1 (bg)	2001-05-31
PL326490A1 (en)	1998-09-28

Legal Events

Date	Code	Title	Description
2002-06-06	MK14	Patent ceased section 143(a) (annual fees not paid) or expired

Publication	Publication Date	Title
DE3650733T2 (de)	2000-05-04	Pharmazeutische Zubereitungen und medizinische Verwendungen von Dioxopiperidinderivaten, insbesondere als Verstärker der Immunantwort sowie als antivirale und antibakterielle Wirkstoffe
HU202108B (en)	1991-02-28	Process for producing pharmaceutical compositions containing serotonine antqgonistic derivatives of indol-carboxylic acid or imidazolyl-methyl-carbazol
WO1994002150A1 (en)	1994-02-03	Use of 1,3-dicyclopropymethyl-8-amino-xanthine for the treatment and prevention of type ii diabetes mellitus and obesity
US20050182089A1 (en)	2005-08-18	Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an N-methyl-D-aspartate (NMDA) receptors antagonist
AU706594B2 (en)	1999-06-17	Treatment of traumatic brain injury
US20080227818A1 (en)	2008-09-18	Use of saredutant or its pharmaceutically acceptable salts in the treatment of mixed anxiety-depression disorders
US6297262B1 (en)	2001-10-02	Treatment of schizophrenia and psychosis
US4845115A (en)	1989-07-04	Method of medical treatment
RU2258506C2 (ru)	2005-08-20	Лекарственные средства для предупреждения и лечения нейродегенеративных заболеваний
US6962921B2 (en)	2005-11-08	Dementia remedies containing 2-aryl-8-oxodihydropurine derivatives as the active ingredient
MXPA98003432A (en)	1998-11-16	Treatment of traumat cerebral damage
HK1018209A (en)	1999-12-17	Treatment of traumatic brain injury
JPH1160482A (ja)	1999-03-02	性機能改善剤